BIOC
Price:
$0.4349
Market Cap:
$0
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cel...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2014-02-05
Stock Exchange
NASDAQ
Ticker
BIOC
According to Biocept, Inc.’s latest financial reports and current stock price. The company's current ROE is -138.49%. This represents a change of -68.87% compared to the average of -444.79% of the last 4 quarters.
The mean historical ROE of Biocept, Inc. over the last ten years is 87.82%. The current -138.49% ROE has changed -257.68% with respect to the historical average. Over the past ten years (40 quarters), BIOC's ROE was at its highest in in the December 2014 quarter at 1.76%. The ROE was at its lowest in in the June 2023 quarter at -1252.07%.
Average
87.82%
Median
-290.96%
Minimum
-2793.44%
Maximum
7.19%
Discovering the peaks and valleys of Biocept, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 9.60%
Maximum Annual ROE = 7.19%
Minimum Annual Increase = -106.38%
Minimum Annual ROE = -2793.44%
Year | ROE | Change |
---|---|---|
2022 | -362.16% | 4.71% |
2021 | -7.53% | -89.53% |
2020 | -71.93% | -67.27% |
2019 | -219.76% | -72.79% |
2018 | -807.61% | -51.57% |
2017 | -1667.68% | -40.30% |
2016 | -2793.44% | 508.60% |
2015 | -459.00% | -106.38% |
2014 | 7.19% | 9.60% |
2013 | 74.13% | 65.58% |
The current ROE of Biocept, Inc. (BIOC) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-147.21%
5-year avg
-293.80%
10-year avg
87.82%
Biocept, Inc.’s ROE is greater than iBio, Inc. (-126.61%), greater than Aytu BioPharma, Inc. (-20.64%), greater than Diffusion Pharmaceuticals Inc. (-44.12%), less than Onconova Therapeutics, Inc. (619.75%), greater than Actinium Pharmaceuticals, Inc. (-100.85%),
Company | ROE | Market cap |
---|---|---|
-126.61% | $21.78M | |
-20.64% | $8.49M | |
-44.12% | $8.98M | |
619.75% | $20.90M | |
-100.85% | $38.68M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biocept, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biocept, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Biocept, Inc.'s ROE?
How is the ROE calculated for Biocept, Inc. (BIOC)?
What is the highest ROE for Biocept, Inc. (BIOC)?
What is the 3-year average ROE for Biocept, Inc. (BIOC)?
What is the 5-year average ROE for Biocept, Inc. (BIOC)?
How does the current ROE for Biocept, Inc. (BIOC) compare to its historical average?